Table 2.
Clinical characteristics associated with class of RAS mutation.
|
RAS/BRAF Wild-type N=1069 |
KRAS Mutant N=1226 |
NRAS Mutant N=127 |
BRAF V600 Mutant N=168 |
P |
RAS/BRAF Wild-type N=1069 |
Exon 2 KRAS Mutation N=1033 |
Extended RAS Mutation N=292 |
Atypical RAS Mutation N=21 |
P | |
|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic | ||||||||||
| Median Age (IQR) | 54 (45–62) | 55 (45–63) | 57 (47–65) | 60 (54–67) | <0.0001 | 54 (45–62) | 55 (45–63) | 57 (47–65) | 55 (45–67) | 0.018 |
| Sex | ||||||||||
| Female | 394 (37%) | 593 (48%) | 65 (51%) | 93 (55%) | <0.0001 | 394 (37%) | 505 (49%) | 137 (47%) | 11 (52%) | <0.0001 |
| Male | 675 (63%) | 633 (52%) | 62 (49%) | 75 (45%) | 675 (63%) | 528 (51%) | 155 (53%) | 10 (48%) | ||
| Location* | ||||||||||
| Right | 216 (20%) | 477 (39%) | 40 (31%) | 116 (70%) | <0.0001 | 216 (20%) | 399 (39%) | 104 (36%) | 10 (48%) | <0.0001 |
| Left | 849 (80%) | 742 (61%) | 87 (69%) | 50 (30%) | 849 (80%) | 631 (61%) | 184 (64%) | 11 (52%) | ||
| MSI Status* | ||||||||||
| MSS | 766 (96%) | 870 (96%) | 99 (99%) | 99 (83%) | <0.0001 | 766 (96%) | 735 (97%) | 218 (96%) | 13 (87%) | 0.25 |
| MSI-H | 30 (4%) | 35 (4%) | 1 (1%) | 20 (17%) | 30 (4%) | 26 (3%) | 8 (4%) | 2 (13%) | ||
| Unknown | 273 | 321 | 27 | 49 | 273 | 272 | 66 | 6 |
*
Percent represent the proportion of patients with a known result for that variable.
Total n=2581 patients, however patients with multiple variants may be included in multiple categories for comparisons between KRAS, NRAS, and BRAF V600 but not RAS mutation class. All RAS mutation categories (atypical, extended, and KRAS exon 2) are grouped together by gene on the left half of the table.
IQR=interquartile range